Celldex Therapeutics, Inc. (NASDAQ:CLDX) Receives $62.25 Consensus PT from Brokerages

Celldex Therapeutics, Inc. (NASDAQ:CLDX) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, Marketbeat reports. Two investment analysts have rated the stock with a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $62.25.

CLDX has been the topic of several recent research reports. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Citigroup assumed coverage on shares of Celldex Therapeutics in a research note on Monday, October 7th. They set a “buy” rating and a $70.00 price target on the stock. Cantor Fitzgerald restated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Thursday, January 2nd. Wolfe Research lowered Celldex Therapeutics from an “outperform” rating to a “peer perform” rating in a report on Friday, September 27th. Finally, The Goldman Sachs Group initiated coverage on Celldex Therapeutics in a research note on Monday, September 30th. They set a “neutral” rating and a $45.00 target price for the company.

Insiders Place Their Bets

In related news, CEO Anthony S. Marucci acquired 11,500 shares of Celldex Therapeutics stock in a transaction dated Monday, November 11th. The shares were acquired at an average cost of $26.82 per share, for a total transaction of $308,430.00. Following the completion of the transaction, the chief executive officer now directly owns 40,284 shares of the company’s stock, valued at $1,080,416.88. The trade was a 39.95 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 3.80% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the company. KBC Group NV boosted its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock worth $71,000 after purchasing an additional 495 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in Celldex Therapeutics during the second quarter worth approximately $76,000. AQR Capital Management LLC grew its stake in Celldex Therapeutics by 23.7% in the 2nd quarter. AQR Capital Management LLC now owns 7,857 shares of the biopharmaceutical company’s stock worth $291,000 after acquiring an additional 1,504 shares during the period. Handelsbanken Fonder AB raised its holdings in Celldex Therapeutics by 23.2% in the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the biopharmaceutical company’s stock valued at $469,000 after acquiring an additional 2,600 shares during the last quarter. Finally, Point72 DIFC Ltd raised its holdings in Celldex Therapeutics by 101.7% in the 3rd quarter. Point72 DIFC Ltd now owns 14,114 shares of the biopharmaceutical company’s stock valued at $480,000 after acquiring an additional 7,116 shares during the last quarter.

Celldex Therapeutics Stock Down 1.6 %

Shares of CLDX stock opened at $24.02 on Wednesday. Celldex Therapeutics has a 52-week low of $22.17 and a 52-week high of $53.18. The stock’s 50-day moving average price is $25.63 and its 200 day moving average price is $31.58. The stock has a market capitalization of $1.59 billion, a PE ratio of -9.35 and a beta of 1.62.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.